000 | 11037cam a22006978i 4500 | ||
---|---|---|---|
001 | on1042076595 | ||
003 | OCoLC | ||
005 | 20220711203437.0 | ||
006 | m o d | ||
007 | cr cnu---unuuu | ||
008 | 180619s2018 nju ob 000 0 eng | ||
010 | _a 2018029535 | ||
040 |
_aDLC _beng _erda _cDLC _dOCLCO _dOCLCF _dN$T _dUKMGB _dDG1 _dRECBK |
||
066 | _c(S | ||
015 |
_aGBB8D4524 _2bnb |
||
016 | 7 |
_a018980288 _2Uk |
|
020 |
_a9781119460459 _q(electronic bk.) |
||
020 |
_a111946045X _q(electronic bk.) |
||
020 |
_a9781119460435 _q(electronic bk. : oBook) |
||
020 |
_a1119460433 _q(electronic bk. : oBook) |
||
020 | _z9781119460459 | ||
020 | _z111946045X | ||
020 | _z9781119460442 | ||
020 | _z1119460441 | ||
020 | _z9781119460107 (hardback) | ||
029 | 1 |
_aUKMGB _b018980288 |
|
035 | _a(OCoLC)1042076595 | ||
037 |
_a9781119460459 _bWiley |
||
042 | _apcc | ||
050 | 4 | _aRS201.N35 | |
072 | 7 |
_aMED _x071000 _2bisacsh |
|
082 | 0 | 4 |
_a615.1/9 _223 |
084 |
_aTEC021000 _2bisacsh |
||
049 | _aMAIN | ||
100 | 1 |
_aSharon, Madhuri, _eauthor. _97725 |
|
245 | 1 | 0 |
_aCarbon dots as theranostic agents / _cMadhuri Sharon and Ashmi Mewada. |
264 | 1 |
_aHoboken, New Jersey : _bWiley-Scrivener, _c[2018] |
|
300 | _a1 online resource. | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bn _2rdamedia |
||
338 |
_aonline resource _bnc _2rdacarrier |
||
490 | 1 | _aAdvances in nanotechnology & applications | |
520 |
_a"Sales handles: - Biocompatible Carbon Dots as a suitable nanoparticle for health care Swarming Carbon dots can cross Blood Brain Barrier and deliver drugs for Neurodegenerative disease Conjugated/functionalized Carbon dots as tri-functional nano-worms for anti-cancer drug delivery, photothermal therapy and bioimaging Also discusses the suitability of Carbon Dots as payload for plant nutrient and drugs Market description: Scientists, researchers, clinicians, and biotechnologists working on theranostics; biomedical industrial sectors working on system biology, diagnostics, imaging, image-guided therapy employing state-of-the-art techniques; and PhD, master and under graduate level courses on therapeutics, biosensors, and translational medicine and personalized medicine"-- _cProvided by publisher. |
||
504 | _aIncludes bibliographical references. | ||
588 | 0 | _aPrint version record. | |
650 | 0 |
_aNanoparticles. _97280 |
|
650 | 0 |
_aNanostructured materials. _94537 |
|
650 | 0 |
_aCarbon. _96451 |
|
650 | 7 |
_aTECHNOLOGY & ENGINEERING / Material Science. _2bisacsh _97726 |
|
650 | 7 |
_aCarbon. _2fast _0(OCoLC)fst00846775 _96451 |
|
650 | 7 |
_aNanoparticles. _2fast _0(OCoLC)fst01032624 _97280 |
|
650 | 7 |
_aNanostructured materials. _2fast _0(OCoLC)fst01032630 _94537 |
|
650 | 7 |
_aMEDICAL / Pharmacology. _2bisacsh _97291 |
|
655 | 4 |
_aElectronic books. _93294 |
|
776 | 0 | 8 |
_iPrint version: _aSharon, Madhuri. _tCarbon dots. _dHoboken, New Jersey : Wiley-Scrivener, [2018] _z9781119460459 _w(DLC) 2018028393 |
830 | 0 |
_aAdvances in nanotechnology & applications. _94711 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1002/9781119460435 _zWiley Online Library |
880 | 0 |
_6505-00/(S _a<p>Preface</p> <p><b>1. Carbon Dots: Discovery, Synthesis and Characterization 1</b></p> <p>1.1. Background 1</p> <p>1.2. Introduction to QD 2</p> <p>1.2.1. What is Quantum Mechanics4</p> <p>1.2.2. Quantum Confinement 7</p> <p>1.2.3. Discovery and History of Carbon Dots 8</p> <p>1.3. Carbon QD and Graphene QD 9</p> <p>1.4. Various Methods of Synthesis of Carbon Dots 10</p> <p>1.4.1. Electrochemical Methods 11</p> <p>1.4.2. Combustion and Thermal Oxidation Method 13</p> <p>1.4.3. Hydrothermal Oxidation Method 15</p> <p>1.4.4. Solvothermal Method 18</p> <p>1.4.5. Laser Ablation of Graphite 18</p> <p>1.4.6. Pulsed Laser Irradiation of Carbon Source 20</p> <p>1.4.7. Arc Discharge Method 20</p> <p>1.4.8. Plasma Treatment 21</p> <p>1.4.9. Opening of Fullerene Cage 22</p> <p>1.4.10. Ultrasonication Method 22</p> <p>1.4.11. Microwave-Assisted Method 23</p> <p>1.4.12. Chemical Methods 26</p> <p>1.4.13. Supported Synthetic Procedure 26</p> <p>1.4.14. Biogenic Method 28</p> <p>1.5. Characterization of Carbon Dots 31</p> <p>1.5.1. Microscopic Methods 32</p> <p>1.5.1.1. SEM and TEM Characterization 32</p> <p>1.5.1.2. AFM and STM Characterization 34</p> <p>1.5.2. Spectroscopic Methods 35</p> <p>1.5.2.1. UV-Vis Spectroscopy and its Application for Band Gap Determination 37</p> <p>1.5.2.2. Fluorescence Spectrometry 37</p> <p>1.5.2.3. Fourier Transform Infrared (FTIR) Spectroscopy 38</p> <p>1.5.2.4. X-Ray Diffraction (XRD) Analysis 40</p> <p>1.5.2.5. X-Ray Photoelectron Spectroscopy (XPS) 41</p> <p>1.5.2.6. Dynamic Light Scattering/Photon Correlation Spectroscopy (DLS/PCS) 41</p> <p>1.5.2.7. Dual Polarization Interferometry (DPI) 42</p> <p>1.5.2.8. Raman Spectroscopy 43</p> <p>1.5.2.9. Nuclear Magnetic Resonance (NMR) Spectroscopy 44</p> <p>1.6. Summary 45</p> <p><b>2. Properties of Carbon Dots 47</b></p> <p>2.1. Introduction 47</p> <p>2.2. Optical Properties 49</p> <p>2.2.1. Absorbance 51</p> <p>2.2.2. Photo-Induced Electron Transfer (PET) with CDs 52</p> <p>2.2.3. Fluorescence/Photoluminescence (PL) 53</p> <p>2.2.3.1. Multiphoton Excitation 60</p> <p>2.2.3.2. Upconversion Photoluminescence 61</p> <p>2.2.3.3. Lack of Blinking 63</p> <p>2.2.3.4. Resistance to Photobleaching 64</p> <p>2.2.4. Photocatalytic Property 65</p> <p>2.3. Chemically Inert 67</p> <p>2.4. Easy Functionalization 67</p> <p>2.5. Water Solubility 68</p> <p>2.6. Low Toxicity 68</p> <p>2.7. Biocompatibility 69</p> <p>2.8. Summary 70</p> <p><b>3. Carbon Dots and Conjugates 71</b></p> <p>3.1. Introduction 71</p> <p>3.2. Why Conjugation of Carbon Dots74</p> <p>3.3. Types of Carbon Dot Conjugates and Their Applications 76</p> <p>3.3.1. Biogenic Compounds Conjugated with Carbon Dots 77</p> <p>3.3.1.1. CDs Conjugated with Proteins/Peptides 78</p> <p>3.3.1.2. CD Conjugates of Amino: Carboxylic Acid Ratio 80</p> <p>3.3.1.3. CDs Conjugated with DNA 80</p> <p>3.3.1.4. CDs Conjugated with RNase and SiRNA 84</p> <p>3.3.1.5. CDs Conjugated with Lipid 86</p> <p>3.3.1.6. CDs Conjugated with Folic Acid 86</p> <p>3.3.1.7. CDs Conjugated with Chitosan 88</p> <p>3.3.1.8. CDs Conjugated with Digitonin 89</p> <p>3.3.2. Inorganic Heteroatoms Conjugated with CDs 90</p> <p>3.3.2.1. CDs Conjugated with Gold Nanoparticles 91</p> <p>3.3.2.2. CDs Conjugated with Silica 92</p> <p>3.3.2.3. CDs Conjugated with ZnO 94</p> <p>3.3.2.4. CDs Conjugated with CdS 95</p> <p>3.3.2.5. CDs Conjugated with Strontium Oxide 96</p> <p>3.3.2.6. CDs Conjugated with Gadolinium(III) 97</p> <p>3.3.2.7. CDs Conjugated with Europium 97</p> <p>3.3.2.8. CDs Conjugated/Doped with Nitrogen, Sulphur, Phosphorus and Boron 99</p> <p>3.3.3. Carbon Dots Conjugated with Organic Material 100</p> <p>3.3.3.1. PEG (Polyethylene Glycol) 101</p> <p>3.3.3.2. CDs Conjugated with PEI (Polyethylenimin) or Polyaziridine 102</p> <p>3.3.3.3. CDs Conjugated with α-Cyclodextrin 105</p> <p>3.3.3.4. CDs Conjugated with Cysteamine 106</p> <p>3.3.3.5. CDs Conjugated with Dihydrolipoic Acid 106</p> <p>3.3.3.6. CDs Conjugated with Polyamidoamine (PAMAM) Dendrimers 107</p> <p>3.3.3.7. CDs Covalently Conjugated with Rhodamine B Dyes 108</p> <p>3.3.3.8. CDs Conjugated with Fe-Aminoclay (FeAC) 109</p> <p>3.3.3.9. CDs Conjugated with MWCNT 109</p> <p>3.3.4. CDs Conjugated with Antibiotics 110</p> <p>3.3.4.1. CDs Conjugated with Ciprofloxacin 111</p> <p>3.3.4.2. CDs Conjugated with Tetracycline 114</p> <p>3.3.4.3. CDs Conjugated with Vancomycin 114</p> <p>3.3.4.4. CDs Conjugated with Ampicillin 115</p> <p>3.3.4.5. CDs Conjugated with Streptomycin 116</p> <p>3.3.5. CDs Conjugated with Anti-Neurodegenerative Drugs for Delivery to Central Nervous System 118</p> <p>3.3.5.1. CDs Conjugated with Haloperidol 119</p> <p>3.3.5.2. CDs Conjugated with Transferrin 124</p> <p>3.3.5.3. CDs Conjugated with Curcumin 125</p> <p>3.3.6. CDs Conjugated with Anticancer Drugs 128</p> <p>3.3.6.1. CDs Conjugated with Doxorubicin 128</p> <p>3.3.6.2. CDs Conjugated with Cisplatin 130</p> <p>3.4. Summary 132</p> <p><b>4. CD as Drug Delivery Vehicle 133</b></p> <p>4.1. Introduction 133</p> <p>4.2. Considerations in Using CD as Drug Delivery Vehicle 136</p> <p>4.3. Designs of CD-Based Drug Delivery System 137</p> <p>4.3.1. Designing for Water-Insoluble Drugs 138</p> <p>4.3.2. Designing for Targeting Tumor Location 138</p> <p>4.3.3. Designing a Theranostic Nanomedicine 139</p> <p>4.3.4. Designing a Photoresponsive Nzzano Drug Delivery System 139</p> <p>4.3.5. Designing for Gene Delivery 140</p> <p>4.3.6. Designing for Antibiotics Delivery 141</p> <p>4.4. Carbon Dots for Delivery of Anti-Cancer Drug 142</p> <p>4.4.1. A Brief Introduction to Cancer 143</p> <p>4.4.2. Necessity of Drug Targeting in Cancer Therapy 144</p> <p>4.4.3. Targeting Angiogenesis with CD 144</p> <p>4.4.4. Various CD Conjugates for Delivering Anti-Cancer Drug 145</p> <p>4.4.5. CD for pH-Dependent Drug Release 146</p> <p>4.4.6. CD for Drug Delivery to Renal Cancer 147</p> <p>4.4.7. CD for Drug Delivery to Lung Cancer 148</p> <p>4.4.8. CD for Drug Delivery to Breast Cancer 149</p> <p>4.5. CD for Drug Delivery to Neurodegenerative Disease 150</p> <p>4.6. CD for Gene Therapy 151</p> <p>4.7. CD to Monitor Delivery of SiRNA 152</p> <p>4.8. Challenges in Using CD as Drug Delivery Vehicle 152</p> <p>4.8.1. Prevention of Drug from Biological Degradation 153</p> <p>4.8.2. Effective Targeting 154</p> <p>4.8.3. Patient Compliance 155</p> <p>4.8.4. Cost Effectiveness 155</p> <p>4.9. Suitability of CD-Conjugated Drugs 156</p> <p>4.9.1. For Oral Drug Delivery 156</p> <p>4.9.2. By Inhalation 156</p> <p>4.9.3. As Transdermal Drug Delivery 157</p> <p>4.9.4. As Injection 157</p> <p>4.10. Summary 157</p> <p><b>5</b><b>. </b><b>Carbon Dots for Cell Imaging and Diagnostics 159</b></p> <p>5.1. Introduction 159</p> <p>5.2. Bioimaging 162</p> <p>5.2.1. Bioimaging of Cancerous Cells 166</p> <p>5.2.1.1. HeLa Cells 168</p> <p>5.2.1.2<b>. </b>Human Breast Cancer MCF-7 Cells and Human Breast Tumor Cells MDA-MB-468 170</p> <p>5.2.1.3<b>. </b>B16F11 and HEK293 Cells 171</p> <p>5.2.1.4<b>. </b>Ehrlich Ascites Carcinoma (EAC) Cells 173</p> <p>5.2.1.5<b>. </b>Human U87 Cell 173</p> <p>5.2.1.6<b>. </b>MGC-803 Human Gastric Cancer Cells 174</p> <p>5.2.1.7<b>. </b>A549 Adenocarcinomic Human Alveolar (Lung) Basal Epithelial Cells 175</p> <p>5.2.1.8<b>. </b>Human Hepatocellular Carcinoma Cells 175</p> <p>5.2.1.9<b>. </b>Kidney Proximal Tubule Cell Line(LLC-PK1) 176</p> <p>5.2.1.10<b>. </b>C6 Glioma Cells 177</p> <p>5.2.2<b>. </b>Bioimaging of Nucleus 178</p> <p>5.2.3<b>. </b>Bioimaging of Virus 180</p> <p>5.2.4<b>. </b>Bioimaging of Bacteria 181</p> <p>5.2.5<b>. </b>Bioimaging of Drosophila melanogaster 183</p> <p>5.3<b>. </b>CDs as Sensor 184</p> <p>5.3.1<b>. </b>Intracellular Detection of Ions 185</p> <p>5.3.1.1<b>. </b>Detection of Ag Ions 185</p> <p>5.3.1.2<b>. </b>CD for Detection of Cu Ion 187</p> <p>5.3.1.3< |
|
942 | _cEBK | ||
994 |
_a92 _bDG1 |
||
999 |
_c68937 _d68937 |